Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 15 | 2025 | 285 | 3.530 |
Why?
|
| Ovarian Neoplasms | 8 | 2024 | 567 | 1.690 |
Why?
|
| Cystadenocarcinoma, Serous | 4 | 2024 | 31 | 1.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2025 | 375 | 1.220 |
Why?
|
| Hysterectomy | 9 | 2025 | 85 | 1.130 |
Why?
|
| Uterine Neoplasms | 3 | 2017 | 70 | 0.980 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 312 | 0.940 |
Why?
|
| Genital Neoplasms, Female | 2 | 2018 | 61 | 0.940 |
Why?
|
| Endometrial Neoplasms | 6 | 2024 | 187 | 0.910 |
Why?
|
| Chemoradiotherapy | 5 | 2025 | 43 | 0.910 |
Why?
|
| Cisplatin | 4 | 2025 | 175 | 0.890 |
Why?
|
| Neoplasm Staging | 13 | 2025 | 463 | 0.870 |
Why?
|
| Prealbumin | 1 | 2022 | 4 | 0.830 |
Why?
|
| Female | 34 | 2025 | 14658 | 0.800 |
Why?
|
| Middle Aged | 23 | 2025 | 6918 | 0.740 |
Why?
|
| Salpingectomy | 3 | 2018 | 8 | 0.630 |
Why?
|
| Aged | 17 | 2025 | 5232 | 0.620 |
Why?
|
| Ovariectomy | 3 | 2018 | 53 | 0.620 |
Why?
|
| Patient Navigation | 1 | 2018 | 5 | 0.600 |
Why?
|
| United States Indian Health Service | 1 | 2018 | 14 | 0.590 |
Why?
|
| Adult | 20 | 2025 | 7510 | 0.580 |
Why?
|
| Humans | 34 | 2025 | 27175 | 0.570 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2014 | 16 | 0.530 |
Why?
|
| Immunotherapy | 1 | 2018 | 139 | 0.530 |
Why?
|
| Retrospective Studies | 9 | 2022 | 2464 | 0.530 |
Why?
|
| Topotecan | 1 | 2015 | 12 | 0.500 |
Why?
|
| Status Epilepticus | 1 | 2015 | 4 | 0.500 |
Why?
|
| Aged, 80 and over | 8 | 2024 | 1943 | 0.470 |
Why?
|
| Leiomyoma | 2 | 2014 | 9 | 0.470 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 133 | 0.440 |
Why?
|
| Indians, North American | 1 | 2018 | 515 | 0.430 |
Why?
|
| Quality of Life | 3 | 2025 | 467 | 0.430 |
Why?
|
| Lymph Nodes | 1 | 2014 | 98 | 0.420 |
Why?
|
| Attitude to Health | 1 | 2014 | 87 | 0.420 |
Why?
|
| Carcinoma | 1 | 2014 | 72 | 0.420 |
Why?
|
| Perception | 1 | 2013 | 85 | 0.420 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 89 | 0.420 |
Why?
|
| Anxiety | 1 | 2013 | 137 | 0.400 |
Why?
|
| BRCA1 Protein | 2 | 2024 | 23 | 0.370 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 283 | 0.360 |
Why?
|
| Uterine Artery Embolization | 1 | 2010 | 2 | 0.350 |
Why?
|
| Pelvis | 3 | 2025 | 37 | 0.340 |
Why?
|
| Fertility Preservation | 2 | 2025 | 8 | 0.300 |
Why?
|
| Lymph Node Excision | 5 | 2025 | 96 | 0.300 |
Why?
|
| Survival Analysis | 2 | 2019 | 279 | 0.290 |
Why?
|
| Young Adult | 4 | 2019 | 2636 | 0.270 |
Why?
|
| Paclitaxel | 2 | 2019 | 184 | 0.270 |
Why?
|
| Pyridines | 2 | 2025 | 102 | 0.270 |
Why?
|
| Feasibility Studies | 2 | 2025 | 191 | 0.250 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2022 | 110 | 0.240 |
Why?
|
| Vaginal Neoplasms | 1 | 2025 | 12 | 0.240 |
Why?
|
| Maintenance Chemotherapy | 1 | 2024 | 15 | 0.230 |
Why?
|
| Postoperative Complications | 3 | 2022 | 607 | 0.230 |
Why?
|
| Indazoles | 1 | 2024 | 16 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 1 | 2025 | 69 | 0.230 |
Why?
|
| Piperidines | 1 | 2024 | 45 | 0.220 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 33 | 0.220 |
Why?
|
| Pilot Projects | 2 | 2022 | 398 | 0.210 |
Why?
|
| BRCA2 Protein | 2 | 2024 | 18 | 0.210 |
Why?
|
| Interleukin-8 | 1 | 2022 | 44 | 0.200 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 31 | 0.200 |
Why?
|
| Vitamin D | 1 | 2022 | 48 | 0.200 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 932 | 0.190 |
Why?
|
| Nomograms | 1 | 2021 | 9 | 0.190 |
Why?
|
| Interleukin-6 | 1 | 2022 | 190 | 0.180 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2021 | 18 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 27 | 0.180 |
Why?
|
| Endometrium | 2 | 2022 | 38 | 0.180 |
Why?
|
| Granulosa Cell Tumor | 1 | 2019 | 3 | 0.170 |
Why?
|
| Ovarian Cysts | 1 | 2019 | 6 | 0.170 |
Why?
|
| Conization | 3 | 2025 | 11 | 0.170 |
Why?
|
| Radiotherapy | 1 | 2019 | 39 | 0.160 |
Why?
|
| Biomarkers | 1 | 2022 | 736 | 0.160 |
Why?
|
| Pituitary Neoplasms | 1 | 2019 | 48 | 0.160 |
Why?
|
| Adenoma | 1 | 2019 | 59 | 0.160 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 287 | 0.150 |
Why?
|
| Patient Compliance | 1 | 2018 | 75 | 0.140 |
Why?
|
| Fallopian Tubes | 1 | 2016 | 14 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 298 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 293 | 0.130 |
Why?
|
| Disease-Free Survival | 3 | 2025 | 225 | 0.130 |
Why?
|
| Neoplasms | 1 | 2024 | 769 | 0.130 |
Why?
|
| Risk Factors | 3 | 2021 | 2043 | 0.130 |
Why?
|
| Seizures | 1 | 2015 | 46 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 3 | 2021 | 180 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2025 | 1224 | 0.120 |
Why?
|
| Uterine Hemorrhage | 1 | 2014 | 9 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 365 | 0.120 |
Why?
|
| Prognosis | 1 | 2017 | 762 | 0.120 |
Why?
|
| Brachytherapy | 2 | 2025 | 50 | 0.110 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 11 | 0.110 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 38 | 0.110 |
Why?
|
| Heterozygote | 1 | 2014 | 64 | 0.110 |
Why?
|
| Premenopause | 1 | 2014 | 20 | 0.110 |
Why?
|
| Gynecology | 1 | 2014 | 56 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 119 | 0.110 |
Why?
|
| Adolescent | 2 | 2018 | 2996 | 0.110 |
Why?
|
| Palliative Care | 1 | 2014 | 79 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2021 | 2289 | 0.110 |
Why?
|
| Medical Oncology | 1 | 2014 | 87 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2014 | 143 | 0.100 |
Why?
|
| Mental Health | 1 | 2013 | 97 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 122 | 0.100 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2012 | 1 | 0.100 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2012 | 5 | 0.100 |
Why?
|
| United States | 1 | 2018 | 2063 | 0.100 |
Why?
|
| Risk | 1 | 2012 | 133 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2025 | 156 | 0.090 |
Why?
|
| Vulvar Neoplasms | 1 | 2011 | 25 | 0.090 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 104 | 0.090 |
Why?
|
| Survival Rate | 2 | 2024 | 412 | 0.080 |
Why?
|
| Time Factors | 1 | 2014 | 1573 | 0.080 |
Why?
|
| Pain Measurement | 1 | 2010 | 163 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 139 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2010 | 160 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 666 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 448 | 0.080 |
Why?
|
| Pregnancy | 2 | 2025 | 1153 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2010 | 597 | 0.070 |
Why?
|
| Age Factors | 2 | 2024 | 724 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 990 | 0.070 |
Why?
|
| Thiosemicarbazones | 1 | 2025 | 5 | 0.060 |
Why?
|
| Lymphedema | 1 | 2025 | 14 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2025 | 35 | 0.060 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 35 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2025 | 76 | 0.060 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 38 | 0.060 |
Why?
|
| Homologous Recombination | 1 | 2024 | 9 | 0.060 |
Why?
|
| Phthalazines | 1 | 2024 | 22 | 0.060 |
Why?
|
| Marijuana Use | 1 | 2024 | 32 | 0.060 |
Why?
|
| Cannabis | 1 | 2024 | 42 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2024 | 64 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2024 | 405 | 0.050 |
Why?
|
| Estriol | 1 | 2022 | 3 | 0.050 |
Why?
|
| Estrone | 1 | 2022 | 5 | 0.050 |
Why?
|
| Everolimus | 1 | 2022 | 16 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2022 | 50 | 0.050 |
Why?
|
| Cervix Uteri | 1 | 2022 | 63 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2022 | 93 | 0.050 |
Why?
|
| Indoles | 1 | 2022 | 98 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 134 | 0.050 |
Why?
|
| Estradiol | 1 | 2022 | 175 | 0.050 |
Why?
|
| Benzamides | 1 | 2021 | 33 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 27 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 217 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 61 | 0.040 |
Why?
|
| Disease Management | 1 | 2021 | 86 | 0.040 |
Why?
|
| Luteinization | 1 | 2019 | 7 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 10 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 189 | 0.040 |
Why?
|
| Ovary | 1 | 2019 | 69 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 92 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 106 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 659 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 368 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 42 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2016 | 26 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2016 | 23 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 202 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 455 | 0.030 |
Why?
|
| Male | 2 | 2024 | 13034 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 151 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2014 | 8 | 0.030 |
Why?
|
| Medical Records | 1 | 2014 | 49 | 0.030 |
Why?
|
| Texas | 1 | 2014 | 134 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 377 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2014 | 93 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2011 | 24 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 141 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 510 | 0.020 |
Why?
|